NCT03052608 2025-11-25A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCPfizerPhase 3 Active not recruiting296 enrolled 28 charts 1 FDA
NCT02767804 2025-10-14eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsXcovery Holdings, Inc.Phase 3 Active not recruiting290 enrolled 1 FDA